Trial Profile

Efficacy and Safety of Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (oFCG) in the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Obinutuzumab (Primary) ; Orelabrutinib (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use

25 Apr 2025 According to an InnoCare Pharma media release, Orelabrutinib received approval from the China National Medical Products Administration (NMPA) for the first-line treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
09 Dec 2024 According to an InnoCare Pharma media release, updated results from this study were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting.
09 Dec 2024 Results presented in the InnoCare Pharma Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com